1 / 42

Director’s Report to the National Advisory Council on Drug Abuse

Director’s Report to the National Advisory Council on Drug Abuse September 10, 2008 Director’s Report to the National Advisory Council on Drug Abuse Budget Update What’s New @ NIH? Recent NIDA Activities NIDA BUDGET (Thousands) 2006 Actual 2008 Est. 2009 P.B. 2007 Budget

jana
Download Presentation

Director’s Report to the National Advisory Council on Drug Abuse

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Director’s Report to the National Advisory Council on Drug Abuse September 10, 2008

  2. Director’s Report to the National Advisory Council on Drug Abuse Budget Update What’s New @ NIH? Recent NIDA Activities

  3. NIDA BUDGET (Thousands) 2006Actual 2008Est. 2009P.B. 2007Budget Authority $698,976 $699,168 $301,532 $1,000,700 +0.1% $700,140 $301,532 $1,001,672 +0.1% $699,852 $300,162 $1,000,014 NonAIDS $299,882 AIDS $998,858 TOTAL Increase Over Prior Year -0.8% +0.6%

  4. What’s New @ NIH? • NIH Leadership Forum • Sept 4, 2008 • Early Stage Investigator (< 10 years from degree) • Effectiveness Research

  5. ESI (avg. age 35) ESI (avg. age 38) Systems Model Suggests 1600 ESI’s Must Enter NIH Workforce to Maintain Average Age Average Age of PI Pool Based on Number of New R01 PI's The average age of the ESI population currently funded is 38 56.0 54.0 52.0 50.0 Age 48.0 Baseline 46.0 44.0 42.0 Age 2006 40.0 1100 1600 2100 2600 Number of New R01 Investigators

  6. No matter the approach, 1500 is the minimum number of New PIs To improve demographic profile of the NIH Workforce, more PIs, at earlier career stages, must be added Setting IC targets -- Possible options: - Percent RPG budget - Success Rate NIH Targets for New Investigators

  7. RFA 2: Epigenomics of Human Health and Disease Aging Development EPIGENOME DISEASE GENOME Environmental Exposure Modifiers of Stress (RFA-RM-08-017) Release/Posted Date: July 16, 2008Application Due Date(s): October 28, 2008 • Trans IC-led demonstration • projects addressing IC related • priorities • Build on reference epigenomes • A total of $8 million in FY 2009 • has been committed to support this FOA • 50/50 RM1.5/IC co-funding, FY09-FY15 • Determine how the epigenome changes with conditions of aging, development, gender, and environmental exposures • Determine how the epigenome changes with diseases or conditions that cross ICs (ie. inflammation, pain, obesity)

  8. Director’s Report to the National Advisory Council on Drug Abuse Budget Update What’s New @ NIH? Recent NIDA Activities

  9. Review Committee: D. Piomelli, Pharm.D., Ph.D. (Chair) University of California, Irvine M.J. Kreek, M.D., Ph.D. Professor, The Rockefeller University P. Kalivas, Ph.D. Medical University of South Carolina R. Nakamura, Ph.D. Deputy Director, NIMH L. Porrino, Ph.D. Wake Forest University School of Medicine Scientific Director Administrative Review Bayview Medical Center April 17 – 18, 2008 “With respect to the scientific vision of Dr. Hoffer, .. the Committee finds his accomplishments in realizing that vision to be highly commendable.” Communication and Cooperation 1. Increase transparency of decision-making processes. 2. Increase interactions among IRP scientists. 3. Use tools of social network analysis to enhance interactions among IRP scientists. Conducting Human Research on Drug Abuse 4. Improve recruiting for protocols. 5. Improve interactions with the NIH IRB 6. Enhance supervision of contract with Maryland Psychiatric Research Center. 7. Extend collaborations with other NIH IC 8. Consider alternative venues for clinical research. Cultural Diversity among IRP Researchers 9. Dr. Hoffer has done a tremendous job at supporting scientific success of minority researchers within the IRP … it is important that he continues to maintain a high level of vigilance on this issue.

  10. NIDA Prevention Research Review Workgroup WORK GROUP MEMBERS CHAIR Mark T. Greenberg, Ph.D.COUNCIL MEMBERS Mary Jane Rotheram-Borus, Ph.D. Marina E. Wolf, Ph.D. ADDITIONAL SENIOR SCIENTISTS Anthony Biglan, Ph.D. Dante Cicchetti, Ph.D. Phil Fisher, Ph.D. Marguerita Lightfoot, Ph.D. Michael Neale, Ph.D. Hilda Pantin, Ph.D. Irwin Sandler, Ph.D. First Meeting Convened on September 8-9, 2008

  11. NIDA 2008 RETREAT Promoting Transformational & Innovational Research June 26-27, 2008 • Subject Team Workgroups • Medications Development • Translational Research • Promoting Infrastructure Utilization • Next Generation of Prevention Research • Next Generation of Genetics/Epigenetics Research • Increase interactions of researchers from different fields • (e.g. statistics + genetics, epidemiology + genetics) • Increase utilization of NIH research infrastructure • Focus on how to translate basic research findings to treatment strategies • (e.g., nicotine findings) • Take proactive steps to attract the best people to NIDA

  12. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Mary Affeldt Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Mary Affeldt Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  13. Ileana Cristea, Ph.D. Assistant Professor in the Department of Molecular Biology, Princeton University Proteomic Tools to Uncover the Role of Chromatin Remodeling in HIV-1 infection Jerome Groopman, M.D. Professor of Medicine, Dina and Raphael Recanati Chair at the Harvard Medical School Chief, Division of Experimental Medicine at the Beth Israel Deaconess Medical Center Inhibition of HIV at the Immune Synapse Utilizing Novel Ligands and Receptors Julio Montaner, M.D. Professor of Medicine, University of British Columbia; Head, Division of AIDS Canada Director, British Columbia Centre for Excellence in HIV/AIDS, Providence Health Care Adjunct Professor, Department of Psychiatry, University of California, San Diego Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDUs

  14. NIDA Sponsored Events: • A Skills Building-Workshop -- “Drug Abuse & HIV/AIDS • Research: Improving Public Health in Latin America” • A Satellite Symposium -- “Drug Abuse and HIV/AIDS • Interventions: An International Perspective” • Extensive Media Coverage including a Press Roundtable • and numerous TV, Radio and Newspaper Interviews with • Drs. Nora Volkow & Jacques Normand

  15. Press Coverage Reached an Estimated 50 million through TV, Radio, Online & Print in the U.S, Mexico, Central & South America Press Roundtable 16 Additional TV, Radio & Magazine Interviews Live Interview on CNN Mexico

  16. Cumulative All-Cause and Non-Accidental Mortality Rate Among Antiretroviral-Naïve Patients Initiating HAART Wood, E et al., JAMA, pp. 550-554, August 15, 2008.

  17. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Mary Affeldt Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Mary Affeldt Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DPMCDA Wilson Compton, MD, MPE David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  18. Medications Development for PolydrugAddiction Treatment (R01–PAS-08-186) (R21--PAS-08-187) Issued June 26, 2008 Medications Development for Cannabis-Related Disorders (R01) (RFA-DA-09-001) Issued April 23, 2008 Pilot Clinical Trialsof Pharmacotherapies for Substance Related Disorders (R01) (RFA-DA-09-005) Issued June 12, 2008 National Cooperative Drug Discovery & Development Groups (NCDDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01/U19) (PAR-08-238) (with NIMH and NIAAA) Issued August 14, 2008

  19. DEVELOPING NEW TOOLS TO PREVENT AND TREAT ADDICTION: Vaccine Development on the Horizon A Congressional Briefing Sponsored by The FRIENDS OF NIDA In conjunction with The Addiction, Treatment and Recovery Caucus Tuesday, July 29, 2008

  20. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Mary Affeldt Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Mary Affeldt Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DESPR David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  21. Reducing Risk Behaviorsby Promoting Positive Youth Development (R01-PA-08-241) (R03-PA-08-242) (with NICHD, NCI and NIAAA) Issued August 15, 2008 Drug AbusePrevention InterventionResearch (R01–PA-08-217) (R21--PA-08-218) (R03--PA-08-219 Issued July 25, 2008 Integrating Biobehavioral & Sociocultural Research to Prevent HIV Transmissionand Infection (R01-PA-08-188) (R21-PA-08-189) (with NINR, NIMH and NIAID) Issued June 30, 2008

  22. Criminal JusticeDrug Abuse Treatment Studies 2 (CJ-DATS 2) (U01) (RFA-DA-09-006) Issued June 24, 2008 ImprovingEffectiveness of Smoking CessationInterventions and Programs in Low Income Adult Populations (R01-RFA-CA-08-022) (R21-RFA-CA-08023) (with NCI) Issued June 18, 2008 Economicsof Treatment and Prevention Services for Drug & Alcohol Abuse (R01-PA-08-174) (R03-PA-08-172) (R21-PA-08-173) (with NIAAA) Issued June 6, 2008

  23. NIDA Resource Guide SBI • Targets adult primary care with a key goal of • increasing screening for illicit drug abuse • Provides a clinician-friendly guide to support • screening and brief intervention • Strengthens clinicians’ ability to discuss screening • results with patients • Brief, graphical introduction to screening and brief intervention steps for primary care providers • Will be on the NIDA website • Recommends the WHO ASSIST (Alcohol, Smoking, and Substance Involvement Screening Test)

  24. Future Manual Development Modify drug categories to emphasize prescription stimulants, sedatives and opioids as separate categories Finish drafting manual -- Introduction -- Appendices -- Pocket Guide Review with clinicians Finalize Disseminate widely

  25. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Mary Affeldt Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network CCTN Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Mary Affeldt Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research Wilson Compton, MD, MPE David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  26. CTSA Clinical & Translational Science Awards Translating Discoveries to Medical Practice 38 Members

  27. NIDA Interactions with CTSAs • Mayo CTSA PI, Bob Rizza, visited NIDA and met with NIDA senior staff on 4/17/08 NIDA Director visited Mayo CTSA 4/28/08 to 4/29/08 NIDA program officers visited Mayo CTSA on 8/5/08 (met with faculty from 7 departments to discuss possible collaborative projects) • Duke CTSA PI, Robert Califf, visited and met with NIDA senior staff on 7/24/08 • Communicated with Harvard CTSA PI, Lee Nadler, and CIO, John Halamka, on EMR 7/2/08 – 7/13/08 (many e-mail communications)

  28. Collaboration with Mayo CTSAThrough Dr. Bob Rizza and Dr. David Warner Mayo Health System PBRN Linkages with Practice-Based Research Network (PBRN) (integrating addiction into medical care settings, pain & opioid addiction, nicotine addiction) • Potential research proposals • smoking, • chronic pain management • screening/brief intervention of SUD in primary care, emergency care and trauma units

  29. Numerous NIDA Interactions with CTSAs • Meeting with extramural investigators to assess opportunities for research on SUD in the CTSA (8/5/08 Mayo; 8/10/08 Duke) • Based on these recommendations NIDA is preparing a Program Announcement with set aside funds (PAS) targeting research within CTSA • Barbara Alving scheduled to speak about the CTSA to the Steering Committee of NIDA’s Clinical Trials Network on 10/21/08 • NIDA NHSN annual meeting invited symposium on “Goals and Milestones of the NIH CTSA” (10/2/08)

  30. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Mary Affeldt Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Mary Affeldt Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DBNBR Wilson Compton, MD, MPE David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  31. Docked Dopamine and “Cocaine" in DAT DAT Dopamine DAT Cocaine Beuming, T. et al., Nature Neuroscience, 11(7), pp. 780-789, 2008.

  32. At the Society for Neuroscience Annual Meeting

  33. NIDA National Institute on Drug Abuse Office of the Director Nora D. Volkow, MD Director Director, AIDS Research Special Populations Office Timothy P. Condon, Ph.D. Deputy Director Mary Affeldt Associate Director for Management Office of Extramural Affairs Office of Planning & Resource Management Office of Science Policy & Communications Center for the Clinical Trials Network Teresa Levitin, PhD Timothy Condon, PhD Betty Tai, PhD Mary Affeldt Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Basic Neurosciences & Behavior Research Intramural Research Program Division of Clinical Neuroscience & Behavioral Research DCNBR Wilson Compton, MD, MPE David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Joseph Frascella, PhD Barry Hoffer, MD, PhD

  34. Brain Imaging Drug Use Prevention Messages (R21) (RFA-DA-07-007) DCNBR & DESPR 16 Applications – 3 funded • Goals • To validate conceptual models of health communication by identifying • neural activation patterns in response to models driven drug-related • persuasive message stimuli • To discern differences in brain and cognitive processes that lead to • differential impact of media messages among populations of children, • adolescents, young adults, and parents varying by factors such as age, • gender, and propensity for risk-taking. • Required collaborative teams of brain imaging and prevention message • investigators

  35. NIDA Blending Conference Evaluation Results Over 1200 Participants Registered

  36. NIDA Scholastic Addiction Science Award At Intel International Science and Engineering Fair • World’s largest high school science fair • Only international student science fair representing all life sciences • 1500 finalists from 50 countries • More than one million students enter at local level • Yi-Han Su, 17, Taipei, China (chemistry) • Natalie Saranga Omattage, 17, USA MI. (bioengineering) • Sana Raoof, 17, USA NY (mathematics)

  37. NIDA NIDA Judges Review the Entries…2 Internal NIDA Staff & 2 NIDA Grantees 1500 entries screened 50 chosen for consideration as addiction-related or deviant behavior- related (based on abstract titles) 8 or 9 interviewed by all judges simultaneously top three selected Cindy Miner, Ph.D. Deputy Director, OSPC, NIDA Genetics Michael Kuhar, Ph.D. Emory University Pharmacology Rochelle Schwartz-Bloom, Ph.D. Duke University Pharmacology Ruben Baler, Ph.D. OSPC, NIDA Molecular Biology

  38. The Novel Role of the GluCl α; Ion Channel & Diazepam Binding Genes in Alcohol Addiction Kapil Vishveshwar Ramachandran – 16 – Austin, TX Wild-type CS acquires behavioral tolerance “Best of Category” Cellular & Molecular Biology Category at ISEF Df-7589 is unable to acquire behavioral tolerance

  39. Video Games: The Next Generation's Addiction Ethan Garrett Guinn – 17 – Moore, OK 385 participants 31% of all participants said that they had reduced their amount of schoolwork accomplished because of video game use 16% of all participants said that they had skipped meals because of video game use 60% of all participants said that they have gone to bed late because of video game use 16% of all participants said that they have spent less time with friends because of video game use 29% of all participants said that they have spent less time with their family because of video game use “Best of Fair” 2008 Oklahoma State Science & Engineering Fair

  40. What's In and What's Out: High Schoolers' Perceptions of Coolness Shelby Marie Raye – 14 – Bradenton, FL American Psychological Association Special Award at ISEF (Third Place)

  41. and encourage schools to place more emphasis on academic achievements How do we get more kids interested in science?? Have them find a topic they like and build a project around it. Addiction Science Award Winners Visit NIH…

  42. NIDA NIDA Follow-Up • Information on winners sent to Congressmen and Senators • Video clips of winners on NIDA’s Website • Invited winners to the Annual Meeting of the Society for Neuroscience Next Year: • Issue request for more projects using modeling or chemistry • Offer summer internships to work with scientists at IRP or with NIDA grantees

More Related